血浆神经丝轻链预测家族性额颞叶变性疾病进展
本研究在277例原始队列和297例验证队列中,检测家族性额颞叶变性(FTLD)突变携带者基线血浆神经丝轻链(NfL)浓度。结果显示,基线NfL升高的无症状携带者短期疾病进展风险更高,且NfL可区分症状性与无症状/前驱期携带者,并与纵向临床和影像学恶化相关。
要点
- 基线血浆NfL升高的无症状FTLD突变携带者短期进展风险显著增加。
- 血浆NfL可区分症状性与无症状或前驱期突变携带者,敏感度和特异度较高。
- 基线NfL越高,纵向CDR+NACC-FTLD评分、神经心理功能和脑萎缩进展越差。
核心结论
- 血浆NfL可识别短期内有疾病进展风险的FTLD突变无症状携带者,并可能用于预防临床试验的受试者筛选。
研究设计与样本
- 研究纳入原始队列277例和验证队列297例,均为来自同一家庭的C9orf72、GRN和MAPT突变携带者及非携带者,使用单分子阵列技术检测基线血浆NfL浓度。
- 采用CDR+NACC-FTLD量表将受试者分为无症状、前驱期和全表型,并用线性混合效应模型分析NfL与临床变量的关系。
主要发现
- 在原始队列中,基线NfL在出现表型转化或疾病进展的无症状突变携带者中为11.4 ± 7 pg/mL,高于未进展者的6.7 ± 5 pg/mL(p = 0.002)。
- 在验证队列中,基线NfL在进展者中为14.1 ± 12 pg/mL,高于未进展者的8.7 ± 6 pg/mL(p = 0.035)。
- 血浆NfL区分症状性与无症状或前驱期突变携带者:原始队列cutoff为13.6 pg/mL,敏感度87.5%,特异度82.7%;验证队列cutoff为19.8 pg/mL,敏感度87.4%,特异度84.3%。
- 较高的基线NfL与纵向CDR+NACC-FTLD评分总和、神经心理功能和萎缩的恶化相关,且不受基因型或疾病严重程度影响,包括无症状突变携带者。
关键数值与推荐
- 原始队列中,基线NfL区分症状性与无症状/前驱期突变携带者的cutoff为13.6 pg/mL,敏感度87.5%,特异度82.7%。
- 验证队列中,基线NfL区分症状性与无症状/前驱期突变携带者的cutoff为19.8 pg/mL,敏感度87.4%,特异度84.3%。
临床怎么用
- 对于家族性FTLD突变携带者,可检测基线血浆NfL以评估短期疾病进展风险。
- 血浆NfL有望作为预防性临床试验中筛选高风险无症状携带者的工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We tested the hypothesis that plasma neurofilament light chain (NfL) identifies asymptomatic carriers of familial frontotemporal lobar degeneration (FTLD)-causing mutations at risk of disease progression. METHODS: Baseline plasma NfL concentrations were measured with single-molecule array in original (n = 277) and validation (n = 297) cohorts. C9orf72, GRN, and MAPT mutation carriers and noncarriers from the same families were classified by disease severity (asymptomatic, prodromal, and full phenotype) using the CDR Dementia Staging Instrument plus behavior and language domains from the National Alzheimer's Disease Coordinating Center FTLD module (CDR+NACC-FTLD). Linear mixed-effect models related NfL to clinical variables. RESULTS: In both cohorts, baseline NfL was higher in asymptomatic mutation carriers who showed phenoconversion or disease progression compared to nonprogressors (original: 11.4 ± 7 pg/mL vs 6.7 ± 5 pg/mL, p = 0.002; validation: 14.1 ± 12 pg/mL vs 8.7 ± 6 pg/mL, p = 0.035). Plasma NfL discriminated symptomatic from asymptomatic mutation carriers or those with prodromal disease (original cutoff: 13.6 pg/mL, 87.5% sensitivity, 82.7% specificity; validation cutoff: 19.8 pg/mL, 87.4% sensitivity, 84.3% specificity). Higher baseline NfL correlated with worse longitudinal CDR+NACC-FTLD sum of boxes scores, neuropsychological function, and atrophy, regardless of genotype or disease severity, including asymptomatic mutation carriers. CONCLUSIONS: Plasma NfL identifies asymptomatic carriers of FTLD-causing mutations at short-term risk of disease progression and is a potential tool to select participants for prevention clinical trials. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT02372773 and NCT02365922. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that in carriers of FTLD-causing mutations, elevation of plasma NfL predicts short-term risk of clinical progression.
引用
- Rojas JC, Wang P, Staffaroni AM, et al. Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology. 2021. PMID: 33827960. doi:10.1212/WNL.0000000000011848
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。